SB 5513 expands the scope of practice for pharmacists in Washington and states legislative findings that pharmacists are highly educated health care professionals who can help address provider shortages, especially in rural and underserved communities. The bill authorizes pharmacists, beginning December 1, to prescribe a defined list of medications and products, including immunizations, opioid antagonists and addiction treatments, epinephrine auto-injectors, antihistamines, tobacco cessation products, HIV prevention medications, tuberculosis testing-related products, hormonal contraception, travel-related medications, and certain drugs, drug categories, or devices that meet specified conditions such as being minor/self-limiting or not requiring a new diagnosis.
The bill also amends existing drug and pharmacy laws to align with this expanded authority and to clarify related definitions and enforcement provisions. It revises the law governing legend drugs, including exceptions for pharmacists acting within their scope, family planning clinics, drug take-back programs, and certain health care professionals. It further authorizes the pharmacy quality assurance commission to adopt rules to administer and implement the act, and includes an expiration date for the new section authorizing pharmacist prescribing.
Overall, the bill would change Washington law by giving pharmacists limited prescribing authority and by updating statutory definitions and penalties tied to legend drugs, pharmacy practice, and related health care delivery. It affects pharmacists, patients seeking more accessible care, and other licensed practitioners whose prescribing authority remains otherwise unchanged. The measure is framed as an access-to-care and public health bill, with an emphasis on chronic disease management and reducing barriers to treatment.
Because no committee transcripts or recorded votes were provided, there is no documented debate or vote history to indicate formal support or opposition. Based on the bill text alone, the tone is strongly favorable toward expanding pharmacist authority and improving access to care. The only apparent policy tension is the scope of pharmacist prescribing and the need to limit it to lower-risk conditions, protocols, and products, which is addressed through detailed eligibility criteria and commission rulemaking.
SB 5513 would amend Washington’s pharmacy and controlled substances-related statutes to permit pharmacists to prescribe certain medications and devices and to clarify when legend drugs may be sold, delivered, possessed, or used by various licensed professionals and programs. It would also authorize the pharmacy quality assurance commission to adopt implementing rules, thereby expanding pharmacists’ legal authority while preserving existing limits on higher-risk prescribing and on other practitioners’ scopes of practice.
The bill’s stated purpose and findings reflect strong support for expanding pharmacists’ role in health care delivery, especially to improve access in rural and underserved areas and to support chronic disease management. No committee discussion or vote record was provided, so there is no evidence of recorded opposition or amendment debate in the supplied materials. The overall sentiment in the bill text is clearly affirmative and access-oriented.
The main potential point of contention is the breadth of the new pharmacist prescribing authority and whether pharmacists should be allowed to prescribe beyond traditional dispensing functions. The bill addresses that concern by limiting prescribing to specified products and conditions, requiring that certain items not require a new diagnosis or be minor/self-limiting, and allowing the pharmacy quality assurance commission to set rules. Another possible issue is how this expansion interacts with physicians, nurse practitioners, physician assistants, and other prescribers, though the bill preserves their existing authority and carves out exceptions for certain settings and programs.